<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791526</url>
  </required_header>
  <id_info>
    <org_study_id>P22-962</org_study_id>
    <nct_id>NCT05791526</nct_id>
  </id_info>
  <brief_title>An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan</brief_title>
  <official_title>A Prospective Observational Study for Evaluation of Safety and Effectiveness of Rinvoq in Moderately to Severely Active Ulcerative Colitis; a Japanese Post-Marketing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon.&#xD;
      Participants with UC have mucosal inflammation starting in the rectum that can extend&#xD;
      continuously to proximal segments of the colon. This study will assess how safe and effective&#xD;
      Rinvoq is in treating adult participants with moderate to severe ulcerative colitis (UC).&#xD;
      Adverse events and change in disease activity will be assessed.&#xD;
&#xD;
      Rinvoq is a drug approved for the treatment of ulcerative colitis (UC). All study&#xD;
      participants will receive Rinvoq as prescribed by their study doctor in accordance with&#xD;
      approved local label. Approximately 300 adult participants will be enrolled in Japan.&#xD;
&#xD;
      Participants will receive upadacitinib as prescribed by their physician according to their&#xD;
      routine clinical practice and local label. Participants will be followed for up to 60 weeks.&#xD;
&#xD;
      There is expected to be no additional burden for participants in this trial. Participants&#xD;
      will attend regular visits during the study at a hospital or clinic according to their&#xD;
      routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Percentage of Serious Infection Reported as Adverse Drug Reaction (ADR)</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Participants Receiving Upadacitinib</arm_group_label>
    <description>Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with moderately to severely active Ulcerative colitis (UC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants diagnosed with moderately to severely active Ulcerative colitis (UC).&#xD;
&#xD;
          -  Participants who are within 14 days from the commencement of Rinvoq treatment for UC.&#xD;
&#xD;
          -  Participants who are administered the first dose of Rinvoq for UC after approval for&#xD;
             UC in Japan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants currently participating in registrational clinical trial.&#xD;
&#xD;
          -  Participants for whom Rinvoq is contraindicated.&#xD;
&#xD;
          -  Participants that have been previously exposed to Rinvoq.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie GK Clinical Trial Registration Desk</last_name>
    <phone>+81-3-4577-1111</phone>
    <email>abbvie_jpn_info_clingov@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fukuoka University Chikushi Hospital /ID# 255248</name>
      <address>
        <city>Chikushino-shi</city>
        <state>Fukuoka</state>
        <zip>818-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hidaka Clinic of Coloproctology /ID# 252879</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>839-0809</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital /ID# 255254</name>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <zip>500-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHO Fukuyama Medical Center /ID# 255246</name>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <zip>720-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo IBD Clinic /ID# 255255</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>064-0919</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima IBD Gastroenterology Clinic /ID# 255191</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>8920804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ishida Clinic of IBD and Gastroenterology /ID# 252878</name>
      <address>
        <city>Oita-shi</city>
        <state>Oita</state>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Naha City Hospital /ID# 255249</name>
      <address>
        <city>Naha-shi</city>
        <state>Okinawa</state>
        <zip>902-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sai Gastroenterology and Proct /ID# 252880</name>
      <address>
        <city>Fujidera-shi</city>
        <state>Osaka</state>
        <zip>583-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital /ID# 255247</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinshukai Infusion Clinic /ID# 253199</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yoshino Medical Clinic /ID# 255192</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>553-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kato Clinic /ID# 254489</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>432-8061</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saiseikai Utsunomiya Hospital /ID# 254488</name>
      <address>
        <city>Utsunomiya-shi</city>
        <state>Tochigi</state>
        <zip>321-0974</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Wakayama Medical Center /ID# 255245</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>640-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.abbvieclinicaltrials.com/study/?id=P22-962</url>
    <description>Related info</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 26, 2023</last_update_submitted>
  <last_update_submitted_qc>April 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <keyword>UC</keyword>
  <keyword>Rinvoq</keyword>
  <keyword>Upadacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

